Evidence map›Paper›PMID 34314900›Full record

ArticleBiomedical journal2022

Discovery of serum biomarkers for diagnosis of tuberculosis by NMR metabolomics including cross-validation with a second cohort.

R Conde, R Laires, L G Gonçalves, A Rizvi, C Barroso, M Villar, R Macedo, M J Simões, S Gaddam, P Lamosa and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Untargeted serum metabolomic profiling for early detection ofFrontiers in cellular and infection microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 3 countries.

R CondeNOVA Institute of Chemical and Biological Technology António Xavier, New University of Lisbon, Oeiras, Portugal.
R LairesNOVA Institute of Chemical and Biological Technology António Xavier, New University of Lisbon, Oeiras, Portugal.
L G GonçalvesNOVA Institute of Chemical and Biological Technology António Xavier, New University of Lisbon, Oeiras, Portugal.
A RizviDepartment of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, India.
C BarrosoCDP Almada-Seixal, ARSLVT, Portugal.
M VillarCDP Venda Nova, ARSLVT, Portugal.
R MacedoINSA, Lisboa, Portugal.
M J SimõesINSA, Lisboa, Portugal.
S GaddamDepartment of Immunology, Bhagwan Mahavir Medical Research Center, Hyderabad, India; Department of Genetics, Osmania University, Hyderabad, India.
P LamosaNOVA Institute of Chemical and Biological Technology António Xavier, New University of Lisbon, Oeiras, Portugal.
L Puchades-CarrascoDrug Discovery Unit, Medical Research Institute-Hospital La Fe, Valencia, Spain.
A Pineda-LucenaDrug Discovery Unit, Medical Research Institute-Hospital La Fe, Valencia, Spain; Molecular Therapeutics Program, CIMA, University of Navarra, Pamplona, Spain.
A B PatelCSIR- Centre for Cellular Molecular Biology, Hyderabad, India.
S C MandeNational Centre For Cell Science, Pune, India; Council of Scientific and Industrial Research, New Delhi, India.
S BanerjeeDepartment of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, India.
M MatzapetakisNOVA Institute of Chemical and Biological Technology António Xavier, New University of Lisbon, Oeiras, Portugal.
A V CoelhoNOVA Institute of Chemical and Biological Technology António Xavier, New University of Lisbon, Oeiras, Portugal. Electronic address: varela@itqb.unl.pt.
University of Lisbon · PTNational Institute of Health Dr. Ricardo Jorge · PTUniversity of Hyderabad · INCâmara Municipal de Almada · PTCentre for Cellular and Molecular Biology · INNational Centre for Cell Science · INOsmania University · INUniversidad de Navarra · ESUniversidade Nova de Lisboa · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTuberculosis (TB) is a disease with worldwide presence and a major cause of death in several developing countries. Current diagnostic methodologies often lack specificity and sensitivity, whereas a long time is needed to obtain a conclusive result.

methodsIn an effort to develop better diagnostic methods, this study aimed at the discovery of a biomarker signature for TB diagnosis using a Nuclear Magnetic Resonance based metabolomics approach. In this study, we acquired

resultsSix metabolites (inosine, hypoxanthine, mannose, asparagine, aspartate and glutamate) were validated by an independent cohort, all of them related with metabolic processes described as associated with TB infection.

conclusionThe findings of the study are according with the WHO Target Product Profile recommendations for a triage test to rule-out active TB.

Indexed as

Aspartic AcidTuberculosisAsparagineBiomarkersGlutamatesHumansHypoxanthinesInosineMagnetic Resonance SpectroscopyMannoseMetabolomicsAsparagineAspartic AcidBiomarkersGlutamatesHypoxanthinesInosineMannoseBiomarkersDiagnosisNMR MetabolomicsSerumTuberculosis

Identifiers

PMID34314900
PMCPMC9486122
OpenAlexW3183563701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.